Sep 23, 2026
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI
Travere Therapeutics announced it has received a US patent allowance for its kidney disease drug, FILSPARI. This development was reported by MT Newswires. The full article is behind a premium paywall.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 22, 2026
Travere Therapeutics Names Bradley Campbell CEO
Travere Therapeutics announced that Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Eric Dube as president and CEO, effective December 1, 2026. Dube, who led Travere's evolution into a rare disease company and achieved significant regulatory approvals, will remain an executive advisor until February 15, 2027, to ensure a smooth transition. Campbell brings over 25 years of biopharmaceutical experience, with a strong focus on rare diseases, and aims to build on Travere's momentum and expand its reach to more patients.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Somewhat-Bullish
Sep 21, 2026
Travere Therapeutics President and CEO Eric Dube Plans to Step Down
Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down. The information was released late Monday by MT Newswires. Further details regarding Dube's departure are available to premium subscribers.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish